CAPP2 highlighted as an Advance in Progress Against Cancer
posted on Thursday, 18th February 2021
Not tagged.
![[#pageName]](/ImageGen.ashx?width=560&image=/media/24594/asco_-_clinical_cancer_advances_2021.jpg)
The CAPP2 clinical trial
led by Professor Sir John Burn, Newcastle University, has been
highlighted by the American Society of Clinical Oncology as an
Advance in Progress Against Cancer in their
16th Annual Report. The CAPP2 long term follow up paper was
published in the
Lancet in 2020.
It is a significant step for this cancer chemoprevention
research to be noted by the American Society of Clinical
Oncology.
CaPP3 is the follow up dose non-inferiority trial to
determine if this cancer chemoprevention can be observed with a
lower dose of aspirin.